Given the effect of PPARα on lipoprotein metabolism, it could be speculated that declining PPARα levels with NAFLD progression [75, 86] contribute to lower MTTP levels and apoB100 secretion rates. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.